Page 135 - 南京医科大学学报自然科学版
P. 135
第44卷第1期 李彦霖,王有民,朱 莉. miR⁃124在常见神经退行性疾病中的作用[J].
2024年1月 南京医科大学学报(自然科学版),2024,44(01):123-129 ·129 ·
[J]. Exp Neurol,2019,314:100-110 展[J]. 基础医学与临床,2022,42(12):1935-1938
[45] SU Y,DENG M F,XIONG W,et al. MicroRNA⁃26a/death⁃ [53] WANG X F,LIU Z J,WANG F. MicroRNA⁃93 blocks sig⁃
associated protein kinase 1 signaling induces synucleino⁃ nal transducers and activator of transcription 3 to reduce
pathy and dopaminergic neuron degeneration in Parkin⁃ neuronal damage in Parkinson’s disease[J]. Neurochem
son’s disease[J]. Biol Psychiatry,2019,85(9):769-781 Res,2021,46(7):1859-1868
[46] LU Y,GONG Z,JIN X,et al. LncRNA MALAT1 targeting [54] ZHANG J F,LU Y X,YUE X P,et al. MiR⁃124 suppresses
miR⁃124⁃3p regulates DAPK1 expression contributes to growth of human colorectal cancer by inhibiting STAT3
cell apoptosis in Parkinson’s disease[J]. J Cell Biochem, [J]. PLoS One,2013,8(8):e70300
2020,121(12):4838-4848 [55] CHENG X J,LI L,XIN B Q. MiR⁃124 Regulates the in⁃
[47] KANAGARAJ N,BEIPING H,DHEEN S T,et al. Down⁃ flammation and apoptosis in myocardial infarction rats by
regulation of miR⁃124 in MPTP⁃treated mouse model of targeting STAT3[J]. Cardiovasc Toxicol,2021,21(9):
Parkinson’s disease and MPP iodide⁃treated MN9D cells 710-720
modulates the expression of the calpain/cdk5 pathway pro⁃ [56] WANG S X,WU G,HAN Y N,et al. miR⁃124 regulates
teins[J]. Neuroscience,2014,272:167-179 STAT3⁃mediated cell proliferation,migration and apopto⁃
[48] DONG R F,ZHANG B,TAI L W,et al. The neuroprotec⁃ sis in bladder cancer[J]. Oncol Lett,2018,16(5):5875-
tive role of miR⁃124⁃3p in a 6⁃hydroxydopamine⁃induced 5881
cell model of parkinson’s disease via the regulation of [57] LOU D N,WANG J,WANG X H. miR⁃124 ameliorates
ANAX5[J]. J Cell Biochem,2018,119(1):269-277 depressive⁃like behavior by targeting STAT3 to regulate
[49]GENG L J,LIU W,CHEN Y.miR⁃124⁃3p attenuates MPP+ microglial activation[J]. Mol Cell Probes,2019,48:
⁃induced neuronal injury by targeting STAT3 in SH⁃SY5Y 101470
cells[J]. Exp Biol Med Maywood N J,2017,242(18): [58] XING R X,LI L G,LIU X W,et al. Down regulation of
1757-1764 miR⁃218,miR⁃124,and miR⁃144 relates to Parkinson’s
[50] MCGEER P L,ITAGAKI S,BOYES B E,et al. Reactive disease via activating NF⁃κB signaling[J]. Kaohsiung J
microglia are positive for HLA⁃DR in the substantia nigra Med Sci,2020,36(10):786-792
of Parkinson’s and Alzheimer’s disease brains[J]. Neu⁃ [59] YAO L P,ZHU Z Y,WU J Y,et al. MicroRNA⁃124 regu⁃
rology,1988,38(8):1285-1291 lates the expression of p62/p38 and promotes autophagy
[51] ARAI H,FURUYA T,MIZUNO Y,et al. Inflammation in the inflammatory pathogenesis of Parkinson’s disease
and infection in Parkinson’s disease[J]. Histol Histo⁃ [J]. FASEB J,2019,33(7):8648-8665
pathol,2006,21(6):673-678 [收稿日期] 2023-07-22
[52] 吴长宝,郝延磊. STAT3与帕金森病发病机制的研究进 (本文编辑:蒋 莉)
(上接第44页)
(3):386-394 [23] SHAHIDA B,JOHNSON P S,JAIN R,et al. Simvastatin
[20] STEIN J D,CHILDERS D,GUPTA S,et al. Risk factors downregulates adipogenesis in 3T3⁃L1 preadipocytes and
for developing thyroid⁃associated ophthalmopathy among orbital fibroblasts from Graves’ophthalmopathy patients
individuals with Graves disease[J]. JAMA Ophthalmol, [J]. Endocr Connect,2019,8(9):1230-1239
2015,133(3):290-296 [24] LANZOLLA G,SABINI E,LEO M,et al. Statins for
[21] SHAN S J C,DOUGLAS R S. The pathophysiology of thy⁃ Graves’orbitopathy(STAGO):a phase 2,open ⁃ label,
roid eye disease[J]. J Neuro Ophthalmol,2014,34(2): adaptive,single centre,randomised clinical trial[J]. Lan⁃
177-185 cet Diabetes Endocrinol,2021,9(11):733-742
[22] WEI Y H,LIAO S L,WANG S H,et al. Simvastatin and [25] MARINÒ M,LANZOLLA G,MARCOCCI C. Statins:a
ROCK inhibitor Y⁃27632 inhibit myofibroblast differen⁃ new hope on the horizon of Graves orbitopathy?[J]. J Clin
tiation of Graves’ophthalmopathy⁃derived orbital fibro⁃ Endocrinol Metab,2021,106(7):e2819-e2821
blasts via RhoA⁃mediated ERK and p38 signaling path⁃ [收稿日期] 2023-07-05
ways[J]. Front Endocrinol(Lausanne),2020,11:607968 (本文编辑:蒋 莉)